首页 | 本学科首页   官方微博 | 高级检索  
     

曲美他嗪在慢性心力衰竭患者中的应用体会
引用本文:秦海燕. 曲美他嗪在慢性心力衰竭患者中的应用体会[J]. 中外医疗, 2016, 0(2): 150-151. DOI: 10.16662/j.cnki.1674-0742.2016.02.150
作者姓名:秦海燕
作者单位:山东省蓬莱市人民医院,山东蓬莱,265600
摘    要:
目的 探讨曲美他嗪在慢性心力衰竭治疗中的临床效果. 方法 该研究随机选取了2014年6月—2015年6月期间该院进行治疗的慢性心力衰竭患者100例作为研究对象,将所有研究对象按照所采取的治疗方式分为观察组和对照组,每组各包含了50例研究对象. 两组患者在入院后均给予常规的抗心力衰竭综合治疗,观察组患者在此治疗基础上,再给予曲美他嗪进行治疗. 结果 观察组患者临床治疗总有效率达到了92.0%,对照组患者仅为70.0%,组间比较差异有统计学意义(P<0.05). 观察组患者治疗后,LVEF、LVEDVI、LVSAVI及E/A等各项超声心动图指标改善程度显著优于对照组患者,组间比较差异有统计学意义(P<0.05). 结论 曲美他嗪治疗慢性心力衰竭能够显著提高患者的临床治疗效果,疗效显著.

关 键 词:曲美他嗪  慢性心力衰竭  临床效果

Application Experience of Trimetazidine in Patients with Chronic Heart Failure
Abstract:
Objective To study the clinical effect of trimetazidine in treatment of chronic heart failure. Methods 100 cases of patients with chronic heart failure treated in our hospital from June 2014 to June 2015 were selected as the research ob-ject and divided into two groups with 50 cases in each according to the different treatment methods, both groups were given combined treatment of anti heart failure after admission, and the observation group were given additional trimetazidine treat-ment on the basis of the control group. Results The total treatment effective rate was 92.0% in the observation group and only 70.0% in the control group, and the difference between groups was statistically significant (P<0.05), after treatment, the improvement degree of various echocardiogram indexes of LVEF, LVEDVI, LVSAVI and E/A were obviously better than those in the control group, and the differences between groups were statistically significant (P<0.05). Conclusion Trimetazidine in treatment of chronic heart failure can obviously improve the patient 's clinical treatment effect and the cu-rative effect is obvious.
Keywords:Trimetazidine  Chronic heart failure  Clinical effect
本文献已被 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号